AG真人官方

BK Technologies Corp. (BKTI) 鈥� Schedule 13G/A (Amendment 1)

The filing discloses that investor Mikhail Stiskin, through his wholly-owned entities Hilve Holdings Ltd. (Cyprus) and Valdor Global DMCC (UAE), now beneficially owns 253,164 BKTI common shares, or 6.9 % of the 3,673,594 shares outstanding as of 8 May 2025. Ownership is held entirely with sole voting and dispositive power; no shares are held jointly.

Breakdown: Hilve Holdings directly holds 220,833 shares (6.0 %); Valdor Global DMCC holds 32,331 shares (0.9 %). The positions exceed the 5 % threshold that triggers a passive Schedule 13G filing, indicating the shares were acquired without intent to influence control of the issuer. The date of the reportable event is 30 Jun 2025, and signatures are dated 5 Aug 2025.

No financial metrics, purchase prices, or transaction dates beyond the ownership snapshot are provided. The filing simply updates beneficial ownership and does not announce any corporate action, change-in-control effort, or strategic agreement.

Smith & Nephew (NYSE:SNN) posted another solid period in its 6-K.

• Q2 2025 revenue rose to $1.553 bn, +7.8% reported (+6.7% underlying); H1 revenue reached $2.961 bn, +4.7% reported (+5.0% underlying) despite two fewer trading days.
• H1 trading profit climbed 11.2% to $523 m; trading margin widened 100 bps to 17.7%, while operating profit jumped 30.6% to $429 m.
• Free cash flow surged to $244 m (H1 2024: $39 m) on 93% cash-conversion; net debt/adj. EBITDA stands at 1.8脳.
• Interim dividend increased 4.2% to 15.0垄 per share and a $500 m share-buyback was announced for H2 2025.
• FY 2025 outlook unchanged: ~5% underlying revenue growth (5.5% reported) and 19-20% trading margin, absorbing a $15-20 m tariff hit.

Growth was broad-based: Orthopaedics +5.0% underlying, Sports Medicine & ENT +5.7%, Advanced Wound Management +10.2%. Recent product launches generated 75% of H1 growth, and the 12-Point Plan cut inventory by $69 m (-46 DSI days). Orthopaedics margin improved 230 bps; Advanced Wound margin +160 bps.

Key risks: China VBP pressure, Emerging-Markets H1 underlying 鈭�0.9%, potential 2026 Medicare changes to skin substitutes, higher trading-tax rate (19.8% vs. 17.8%) and $15-20 m tariff headwind. Nonetheless, operational gains and balance-sheet strength underpin continued cash returns.

SEC Form 3 filing for IDEAYA Biosciences (IDYA): Newly appointed Chief Financial Officer Joshua Bleharski has disclosed his initial beneficial ownership. The filing shows 250,000 stock options with an exercise price of $20.05 per share. Vesting begins 25 % on May 1 2026, with the remaining shares vesting monthly in equal installments over 36 months, reaching full vesting by May 1 2029. No non-derivative common shares are reported at this time, and the options are held directly. This Form 3 is procedural, establishing the CFO鈥檚 ownership under Section 16(a) of the Exchange Act; it does not include financial performance data or indicate any corporate transactions.

IDEAYA Biosciences (Nasdaq: IDYA) filed an 8-K disclosing a material C-suite change. On June 26 2025, the Board appointed Joshua Bleharski, Ph.D. as Chief Financial Officer and Principal Financial Officer under Item 5.02. The filing states the appointment is effective immediately and made pursuant to Section 16(a)-1(f) of the Exchange Act.

No resignations, compensation terms, financial guidance or other business updates were provided. Investors should monitor upcoming filings for any strategic or financial initiatives led by the new CFO.

IDEAYA Biosciences (IDYA) director Wendy L. Yarno received a stock option grant for 20,000 shares of common stock on June 24, 2025. The options were granted with an exercise price of $21.78 per share and will expire on June 24, 2035.

Key terms of the option grant:

• Vesting occurs at the earlier of: (1) first anniversary of grant date or (2) immediately before the next Annual Meeting
• Vesting is contingent on continued Board service
• The options represent a direct ownership form

This Form 4 filing was submitted by Andres Ruiz Briseno as attorney-in-fact for Yarno on June 26, 2025, meeting the SEC's two-day reporting requirement for insider transactions.

IDEAYA Biosciences (IDYA) Director Jeffrey Stein received a new stock option grant on June 24, 2025. The grant consists of 20,000 stock options with an exercise price of $21.78 per share.

Key details of the option grant:

• Expiration date: June 24, 2035
• Vesting schedule: 100% vests on earlier of (i) first anniversary of grant date or (ii) immediately before next Annual Meeting
• Vesting contingent on continued Board service

This Form 4 filing, signed by Attorney-in-Fact Andres Ruiz Briseno on June 26, 2025, represents standard equity compensation for non-employee director service. The grant aligns the director's interests with shareholders through long-term equity ownership.

IDEAYA Biosciences (IDYA) director Malcolm Garret Hampton received a new stock option grant on June 24, 2025. The grant consists of:

• Options to purchase 20,000 shares of common stock
• Exercise price set at $21.78 per share
• Expiration date of June 24, 2035

The options feature an accelerated vesting schedule, with 100% vesting occurring at the earlier of: (1) the first anniversary of the grant date, or (2) immediately before the next Annual Meeting, contingent on Hampton's continued board service. This grant appears to be part of the company's standard director compensation program. The transaction was reported via Form 4 filed by Hampton's attorney-in-fact, Andres Ruiz Briseno.

IDEAYA Biosciences, Inc. (IDYA) filed a Form 4 disclosing that Director Scott W. Morrison received an equity incentive on 24 June 2025. The award is a stock option for 20,000 common shares at an exercise price of $21.78 per share, expiring on 24 June 2035. According to the vesting schedule, 100 % of the option vests on the earlier of (i) the one-year anniversary of the grant date or (ii) immediately prior to the next annual meeting, provided the director remains on the Board. After this grant, Morrison beneficially owns 20,000 derivative securities; no non-derivative shares were bought or sold. The filing reflects routine director compensation aimed at aligning governance incentives with shareholder interests and does not immediately alter the company鈥檚 share count or cash position.

Iron Mountain Inc. (NYSE: IRM) 鈥� Form 144 filing: CEO William L. Meaney has filed a notice of proposed sale for 69,125 common shares through Fidelity Brokerage, with an aggregate market value of roughly $7.05 million. The shares represent only 0.023% of the company鈥檚 295.0 million shares outstanding. The anticipated sale date is 01 July 2025.

The filing shows the shares were acquired via an option granted on 18 Feb 2016 and exercised on 01 July 2025, paid in cash. Meaney has already sold 207,375 shares over the last three months (01 Apr, 02 May, 02 Jun 2025) generating 鈮� $19.5 million in gross proceeds. The current notice is therefore a continuation of an ongoing liquidation program, likely under a Rule 10b5-1 trading plan (the form requests plan-adoption date but leaves that field blank).

Because Form 144 is only a notice of intent, the sale may or may not be completed. While insider selling by the CEO can draw investor attention, the percentage of total shares is immaterial and does not directly affect the company鈥檚 capital structure or operations. Investors should watch subsequent Form 4 filings to confirm execution and to gauge any larger trend in executive share disposition.